IMMU-08. reMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET)

A phase II study was performed to assess vaccine-related toxicities and efficacy of x-ALT+tt-RNA DC following MAC +PBSC (group A) or NMAC +PBSC (group B) in pts with r-PNET. METHODS: Eligible pts underwent biopsy to confirm r-PNET and obtain tumor for vaccine preparation. Pts with local (group A) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Gururangan, Sridharan, Hwang, Eugene, Dhall, Girish, Yegorov, Oleg, Governale, Lance, Blatt, Jason, Horn, Biljana, Mitchell, Duane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715134/
http://dx.doi.org/10.1093/neuonc/noaa222.364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715134/
http://dx.doi.org/10.1093/neuonc/noaa222.364

Ejemplares similares